ProKidney Corp. (PROK)
NASDAQ: PROK · Real-Time Price · USD
2.710
+0.180 (7.11%)
At close: Sep 18, 2025, 4:00 PM EDT
2.730
+0.020 (0.74%)
After-hours: Sep 18, 2025, 7:55 PM EDT
ProKidney Revenue
ProKidney had revenue of $221.00K in the quarter ending June 30, 2025. This brings the company's revenue in the last twelve months to $527.00K. In the year 2024, ProKidney had annual revenue of $76.00K.
Revenue (ttm)
$527.00K
Revenue Growth
n/a
P/S Ratio
1,510.50
Revenue / Employee
$2,583
Employees
204
Market Cap
797.51M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 76.00K | - | - |
Dec 31, 2023 | - | - | - |
Dec 31, 2022 | - | - | - |
Dec 31, 2021 | - | - | - |
Dec 31, 2020 | - | - | - |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
PROK News
- 10 days ago - ProKidney Corp. (PROK) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript - Seeking Alpha
- 15 days ago - ProKidney Corp. (PROK) Presents At Citi's Biopharma Back To School Conference Transcript - Seeking Alpha
- 22 days ago - ProKidney to Participate in Two Upcoming Conferences: the Citi Biopharma Back to School Conference and the Morgan Stanley Global Healthcare Conference - GlobeNewsWire
- 5 weeks ago - ProKidney Reports Second Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates - GlobeNewsWire
- 2 months ago - ProKidney Announces Alignment with the FDA on the Accelerated Approval Pathway for Rilparencel - GlobeNewsWire
- 2 months ago - ProKidney: What's Happening With PROK Stock? - Forbes
- 2 months ago - ProKidney to Participate in the H.C. Wainwright 4th Annual Kidney Virtual Conference - GlobeNewsWire
- 2 months ago - ProKidney's stock rockets on ‘intriguing' news, but analyst doesn't recommend buying - Market Watch